The Effect of 3 Ropivacaine Suprascapular Nerve Blocks in Subacute Adhesive Capsulitis: a Randomized Controlled Trial
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
Patients presenting with subacute, less than 6 months of evolution, adhesive capsulitis are
randomly attributed to the control or study group. Both groups receive a series of 3
suprascapular nerve blocks under ultrasound guidance with either 5ml saline or 5ml
ropivacaine 2mg/ml ( ref) at 1 week interval. Testing consists of glenohumeral range of
motion (ROM) (anterior elevation, lateral elevation, external and internal rotation) measured
by goniometer, Constant score and visual analog scale (VAS) pain score. Evaluations are done
immediately before and one hour after every suprascapular block and at 4 weeks after the
third suprascapular block.
All suprascapular nerve blocks are performed by one physician and the evaluations are done by
a occupational therapist or MD experienced in glenohumeral function evaluations. All
practitioners are blinded to the assigned group.
All patients continue their pre-study treatment of physiotherapy and per os pain medication.
Patients keep a record of analgesics and NSAID use during the trial. Drop-out rate is
measured.